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Abstract The objective of this review was to determine
the effectiveness of pharmacological interventions [i.e.,
non-steroid anti-inﬂammatory drugs (NSAIDs), muscle
relaxants, antidepressants, and opioids] for non-speciﬁc
chronic low-back pain (LBP). Existing Cochrane reviews
for the four interventions were screened for studies ful-
ﬁlling the inclusion criteria. Then, the literature searches
were updated. Only randomized controlled trials on adults
(C18 years) with chronic (C12 weeks) non-speciﬁc LBP
and evaluation of at least one of the main clinically rele-
vant outcome measures (pain, functional status, perceived
recovery, or return to work) were included. The GRADE
approach was used to determine the quality of evidence.
A total of 17 randomized controlled trials was included:
NSAIDs (n = 4), antidepressants (n = 5), and opioids
(n = 8). No studies were found for muscle relaxants; 14
studies had a low risk of bias. The studies only reported
effects on the short term (\3 months). The overall quality
of the evidence was low. NSAIDs and opioids seem to lead
to a somewhat higher relief in pain on the short term, as
compared to placebo, in patients with non-speciﬁc chronic
low back pain; opioids seem to have a small effect in
improving function for a selection of patients who
responded with an exacerbation of their symptoms after
stopping their medication. However, both types of medi-
cation show more adverse effects than placebo. There
seems to be no difference in effect between antidepressants
and placebo in patients with non-speciﬁc chronic LBP.
Keywords Systematic review  Medication 
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Interventions
Introduction
Low-back pain (LBP) is related to disability and work
absence and accounts for high economical costs in Wes-
tern societies [1]. The management of LBP comprises a
range of different intervention strategies including sur-
gery, non-medical interventions such as exercise, behav-
ioral therapy, and alternative therapies. Pharmacological
interventions are the most frequently recommended
intervention for back pain [2, 3]. Over the last years, a
substantial number of randomized clinical trials and sys-
tematic reviews have been published. Based on this lit-
erature, this overview presents the current evidence on
pharmacological interventions for non-speciﬁc chronic
low back pain.
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The objective of this review was to determine the effec-
tiveness of pharmacological interventions [i.e., non-steroid
anti-inﬂammatory drugs (NSAIDs), muscle relaxants,
antidepressants, and opioids] for non-speciﬁc chronic LBP.
Criteria for considering studies for this review
Types of studies
Only randomized controlled trials with at least 1 day of
follow-up were considered in this systematic review.
Types of participants
In order to be included in this review, participants of the
RCTs must fulﬁll the following inclusion criteria: adult
subjects (C18 years of age) with chronic ([12 weeks) non-
speciﬁc LBP (including discopathy or any other non-spe-
ciﬁc degenerative pathology such as osteoarthritis).
The exclusion criteria were: (1) trials including subjects
with speciﬁc LBP caused by pathologies such as vertebral
spinal stenosis, ankylosing spondylitis, scoliosis, and coc-
cydynia the diagnosis of which had to be conﬁrmed by an
MRI or another diagnostic imaging tool; (2) post-partum
LBP or pelvic pain due to pregnancy; (3) post-operative
studies;
1 (4) prevention studies; and (5) abstracts or non-
published studies.
Types of interventions
The RCTs studying the following interventions were inclu-
ded in this overview: NSAIDs, muscle relaxants, antide-
pressants, and opioids. All types of NSAIDs (including
COX-2), antidepressants (i.e., tricyclic and heterocyclic
antidepressants, selective serotonin reuptake inhibitors,
mono-amine oxidase inhibitors and ‘atypical’ antidepres-
sants), muscle relaxants and opioids [given by oral, trans-
dermal, mucosal (nasal or rectal), or intramuscular routes]
were included.
Additional interventions were allowed in all studies if
there was a contrast for the pharmacological intervention in
the study.
Types of outcome measures
For inclusion, at least one of the following outcome mea-
sures should have been measured in the RCT: pain
intensity [e.g., visual analog scale (VAS), numerical rating
scale (NRS), McGill pain questionnaire], back-speciﬁc
functional status (e.g., Roland–Morris Disability Ques-
tionnaire, Oswestry Disability Index), perceived recovery
(e.g., overall improvement), and return to work (e.g., return
to work status, sick leave days). The primary outcomes for
this review were pain and functional status.
Search methods for identiﬁcation of studies
Existing Cochrane reviews for the four interventions were
screened for studies fulﬁlling the inclusion criteria [4–7].
Then, the literature searches were updated from the last
date onward for each of the interventions.
The search was conducted in MEDLINE, EMBASE,
CINAHL, CENTRAL, and PEDro up to December 22,
2008. References of relevant studies were screened, and
experts were approached in order to identify additional
primary studies not identiﬁed in the previous steps. The
language was limited to English, Dutch, and German,
because these are the languages that the authors are able to
read and understand. The search strategy outlined by the
Cochrane Back Review Group (CBRG) was followed and
is available upon request from the primary author [8].
Methods of the review
Study selection
Three authors (TK, SMR, and MM) independently
screened the abstracts and titles retrieved by the search
strategy and applied the inclusion criteria to all these
abstracts. The ﬁrst author screened all abstracts (TK), the
others both half of the references. Full text of the article
was obtained if the title and the abstract seemed to fulﬁll
the inclusion criteria or if eligibility of the study was
unclear. All full text articles from the existing Cochrane
reviews were compiled and screened on inclusion criteria
by the authors, independently. Any disagreements between
the authors were resolved by discussion and consensus.
Risk-of-bias assessment
Two reviewers (TK and SMR) assessed the risk of bias
(RoB) independently, using the criteria list advised by the
CBRG, which consists of 11 items [8]. Items were scored
as ‘positive’ if they fulﬁlled the criteria, as ‘negative’ when
there was a clear RoB, and as ‘inconclusive’ if there was
insufﬁcient information. Differences in assessment were
discussed during a consensus meeting. A total score was
computed by adding the number of positive scores, and
1 For opioids only studies speciﬁcally studying post-operative
patients were excluded.
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123high quality was deﬁned as fulﬁlling 6 or more (more than
50%) of the 11 internal validity criteria [9].
Data extraction
A standardized form was used for data extraction consist-
ing of both descriptive data on the study population, the
type of intervention examined, and quantitative data
regarding the outcome measures. Data on the characteris-
tics of the study population (gender, age), type and dose of
medication, control treatment, and study results were also
described.
Data analysis
If studies were clinically homogeneous regarding study
population, types of treatment, reference treatment, out-
comes, and measurement instruments, a meta-analysis was
performed. If possible, we calculated the weighted mean
difference (WMD) because this improves the interpret-
ability of the results. If a WMD was not possible the
standardized mean difference (SMD) was calculated. If
trials reported outcomes as graphs, the mean scores and
standard deviations (SDs) were estimated from these
graphs. If SDs were not reported, they were calculated
using the reported values of the conﬁdence intervals, if
possible. If the SD of the baseline score was reported, we
used the ratio between the baseline score and SD to cal-
culate the SD for other follow-up moments. Finally, if none
of these data were reported, an estimation of the SD was
based on study data (population and score) of other studies.
In order to correct for error introduced by ‘‘double-count-
ing’’ of subjects of ‘‘shared’’ interventions (i.e., two com-
parisons within one study that used the same control group
as contrast) in the meta-analyses, the number of subjects in
similar contrasts was divided by the number of compari-
sons that this one study added in the meta-analyses. For the
comparisons where studies were clinically too heteroge-
neous, no meta-analysis was performed. We chose for
random effect model when inspection of the forest plots
showed heterogeneity represented by different directions of
the effects or if I
2[20% (arbitrary cutoff point). When no
new studies were added to the results of the original
reviews we followed the presentation of the original
results. Heterogeneity was tested with Chi-square and I
2.
For the statistical analyses the software package ‘Review
Manager 5’ was used.
Quality of the evidence
Grades of Recommendation, Assessment, Development,
and Evaluation (GRADE) was used to evaluate the over-
all quality of the evidence and the strength of the
recommendations [10]. Quality of the evidence for a spe-
ciﬁc outcome was based upon ﬁve principal factors:
(1) limitations (e.g., due to study design), (2) inconsistency
of results, (3) indirectness (e.g., generalizability of the
ﬁndings), (4) imprecision (e.g., sufﬁcient data), and (5)
other considerations, such as reporting bias. The overall
quality was considered to be high when multiple RCTs
with a low RoB provide consistent, generalizable, precise
data for a particular outcome. The quality of the evidence
was downgraded by one level when one of the factors
described above was not met [10]. Single studies were
considered imprecise (i.e., sparse data) and provide ‘‘low
quality evidence’’, which could be further downgraded to
‘‘very low quality evidence’’ if there were also limitations
in design or indirectness. The following grades of quality
of the evidence were applied:
High quality Further research is very unlikely to
change our conﬁdence in the estimate
of effect.
Moderate quality Further research is likely to have an
important impact on our conﬁdence in
the estimate of effect and may change
the estimate.
Low quality Further research is very likely to have
an important impact on our conﬁdence
in the estimate of effect and is likely to
change the estimate.
Very low quality We are very uncertain about the
estimate.
To improve the readability of this review, a GRADE
table was only completed when we completed a meta-
analysis. If only one study was present for a given com-
parison, the results are described in the text and in the table
with characteristics of included studies.
Adverse events were reported using relative risk (RR)
for the total number of any adverse event.
Results
Description of studies
Study selection
A total of 17 studies was included in this review (Fig. 1).
From the four existing Cochrane reviews a total of 109
references was screened for eligibility. Of these 109 arti-
cles, 12 studies fulﬁlled the inclusion criteria and were
included in this overview (Fig. 1). The most important
reason for exclusion was inclusion of acute patients in the
study. Additionally, 156 potentially new relevant titles and
abstracts were identiﬁed for the four pharmacological
42 Eur Spine J (2011) 20:40–50
123interventions and screened for potential inclusion. Of these
abstracts, 11 full text articles were evaluated. A total of ﬁve
studies fulﬁlled the inclusion criteria and were therefore
included. The study characteristics of all included and
excluded studies are summarized in Appendix 1 in Elec-
tronic Supplementary Material.
NSAIDs Four studies compared one or more types of
NSAIDs with a placebo [11–14]. NSAIDs that were used in
the studies were naproxen, etoricoxib, rofecoxib, and val-
decoxib. In three [12–14] of the four studies selective
COX-2 NSAIDs were studied. In three [12–14] of the four
studies assessing NSAIDs for chronic LBP a so called
‘‘ﬂare design’’ was used, in which patients who were
already responding well to NSAIDs were only included
when they showed a large worsening in LBP complaints
during a wash-out period.
Potentially relevant publications identified and screened for retrieval (n=156) 
NSAID’s (n=9) 
Muscle Relaxants (n=35) 
Antidepressants (n=56) 
Opioids (n=56) 
Full text articles evaluated (n=11): 
Muscle relaxants (n=1) 
Antidepressants (n=2) 
Opioids (n=8) 
Publications included (n=5): 
Muscle Relaxants (n=0)
Antidepressants (n=1) 
Opioids (n=4) 
Papers excluded on basis of  
title and abstract (n=145) 
Excluded (n=6): 
- Specific LBP (n=1) 
- No contrast (n=2) 
- Follow-up < 1 day (n=1) 
- Postoperative patients (n=2) 
Total included studies (n=17) 
NSAIDs (n=4) 
Muscle Relaxants (n=0) 
Antidepressants (n=5) 
Opioids (n=8)
Articles from existing 
Cochrane reviews (n=12): 
- NSAIDs (n=4) 
- Muscle Relaxants (n=0) 
- Antidepressants (n=4) 
- Opioids (n=4) 
Fig. 1 Flow diagram of
inclusion and exclusion of
articles for pharmacological
interventions for chronic low
back pain
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123Antidepressants Five studies were identiﬁed that com-
pared antidepressant medication with placebo [15–19].
Two studies by Atkinson [16, 19], each included several
comparisons, including different types of antidepressants
with placebo and two antidepressants with each other. In
the current review, we included two placebo comparisons
from Atkinson [16] of maprotiline, and paroxetine, which
we respectively refer to in our analysis as Atkinson [16].
We included three placebo comparisons from Atkinson
[19] of desipramine\60 ng/mL (analysis: Atkinson [19]),
desipramine [60 ng/mL (analysis: Atkinson [19]) and
ﬂuoxetine (analysis: Atkinson [19]).
All studies included patients because they had back pain,
but only one study explicitly selected low-back patients
with signiﬁcant depressive symptoms [17]. Three studies
excluded patients with major depression [15, 16, 19], and
in one study it was unclear if patients were depressed
or not [18].
Several types of antidepressants were investigated:
tricyclic antidepressants (TCAs), serotonin selective reup-
take inhibitors, and ‘atypical’ antidepressants (e.g., ami-
noketone antidepressants) [20, 21]. Most studies evaluated
the effectiveness of TCAs with noradrenergic (maprotiline,
nortriptyline, desipramine) [15, 16, 19]. Three studies
evaluated a selective serotonin reuptake inhibitor (paroxe-
tine, ﬂuoxetine) [16, 17, 19] and one study investigated
‘atypical’ antidepressants, bupropion (aminoketone antide-
pressant) [18]. While two trials used an active placebo (i.e.,
preparation containing substances that mimic the adverse
effects of antidepressants) [16, 19], the other trials used an
inert placebo [15, 17, 18]. In all studies patients were
allowed to continue regular medication (e.g., aspirin,
NSAIDs), although opioids were usually not allowed.
One study reported little or no information on additional
medication [18].
Opioids Seven double-blinded RCTs compared opioids
to inactive placebo in the management of chronic LBP
[22–28]. Peloso [24] and Schnitzer [22] excluded patients
with spinal stenosis, spondylolisthesis (Grade 2 or higher
for Peloso [24]), and symptomatic disc herniation. Three
trials were sponsored by Ortho-McNeil Pharmaceutical
[22–24] and two by Endo Pharmaceuticals [25, 26].
Only one trial excluded patients with a history of lumbar
spine surgery [28]. Two trials allowed patients with
previous low-back surgery if it was performed more than
5 years previously and only if it was associated with
complete pain relief [22, 24]. Three trials excluded patients
with major surgery in the preceding 2 months [25],
3 months [27] or 6 months [26]. One study [23] did not
report information about the surgery history of participants.
Tramadol (an atypical weak opioid) was the active agent
in four studies [22–24, 28] with two studies using a
combination tablet containing acetaminophen (paraceta-
mol) [23, 24]. Vorsanger [28] also compared two different
doses of tramadol 200 mg (Vorsanger [28] in analysis) and
300 mg (Vorsanger [28] in analysis). The average daily
dose of tramadol in the other studies was approximately
150 mg [23, 24] or 242 mg [22]. In two studies [26, 27] the
opioid oxymorphone extended release (ER) was studied. In
one study the opioid oxytrex (oxycodone plus ultra low-
dose naltrexone) was studied [27]. This study had three
intervention arms: oxycodone qid (Webster [27]); oxytrex
qid (Webster [27]); and oxytrex bid (Webster [27]).
Only one trial [29] included in this review assessed the
effectiveness of opioids as compared to another analgesic
(i.e., naproxen).
In ﬁve of the eight studies a so called ‘‘ﬂare design’’ was
used, in which patients who were already responding well
to opioids were only included when they showed a large
worsening in LBP complaints during a wash-out period.
Risk of bias in included studies
The results of the risk-of-bias assessment are shown in
Table 1. Fourteen studies (82%) had a low RoB. All studies
were described as randomized; however, only seven studies
(41%) used an adequate randomization procedure in com-
bination with an adequate concealment of treatment allo-
cation. In only seven studies (41%) co-interventions were
avoided or similar. Especially in the studies regarding
NSAIDs and antidepressants this item was very poorly
reported. Many studies had unacceptable compliance
(10studies;59%)orunacceptabledrop-outrates(11studies;
67%) or both (8 studies; 41%).
Effects of intervention
A summary of the effect estimates can be found in Table 2.
In addition, ﬁgures pertaining to the meta-analyses are
available for all the studied interventions in Appendix 3 in
Electronic Supplementary Material.
NSAIDs
NSAIDs versus placebo: pain intensity All four studies,
which compared NSAIDs with placebo for chronic LBP
reported sufﬁcient data on pain intensity to enable statis-
tical pooling. The Chi-square value for homogeneity of the
WMD was 1.82 (P[0.5), indicating statistical homoge-
neity among these studies.
There is low-quality evidence (four RCTs; n = 1,020;
limitations in design; indirectness) that NSAIDs are more
effective than placebo (WMD -12.40; 95% CI -15.53 to
-9.26) (Appendix 3, graph 01.01 in Electronic Supple-
mentary Material).
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123The four studies also reported data on adverse effects,
the Chi-square value for homogeneity of the RR for
adverse effects was 1.01 (df = 3; P[0.5), indicating
homogeneity among the studies. There is low-quality
evidence (four RCTs; n = 1,034; limitations in design;
indirectness) that there are statistically signiﬁcant more
adverse effects in the NSAIDs group (RR 1.24; 95% CI
1.07–1.43) (Appendix 3, graph 01.02 in Electronic Sup-
plementary Material).
In a sensitivity analysis, we assessed the inﬂuence on the
results if we leave out the study of Berry (1982), which
studied traditional NSAIDs instead of COX-2 NSAIDs. We
found no differences in effect estimates as compared with
our main analysis (data available on request).
Antidepressants
Antidepressants versus placebo: pain intensity Of the ﬁve
low-risk-of-bias studies comparing antidepressants with
placebo, three trials reported no differences in pain
between these treatments [16–18], while a treatment arm of
Atkinson’s 1999 study and two more low-risk-of-bias
studies reported a greater reduction in pain with the use of
antidepressants [15, 16, 19]. A meta-analysis of four small
placebo-controlled trials was performed [16–19], which
included two studies by Atkinson [16, 19] with two and
three intervention arms, respectively. One trial was exclu-
ded in the meta-analysis as follow-up means and SDs were
not reported [15]. The Chi-square value for homogeneity of
the SMD was 4.57 (df = 6; P = 0.60), indicating statisti-
cal homogeneity among the studies. There is moderate
quality evidence (four RCTs; n = 292; limitations in
design) that there is no difference in pain relief between
antidepressants and placebo for patients with chronic non-
speciﬁc LBP (SMD -0.02; 95% CI -0.26 to 0.22)
(Appendix 3, graph 02.01 in Electronic Supplementary
Material).
Antidepressants versus placebo: depression Four trials
with a low RoB included depression as an outcome, which
was measured by the Beck Depression Inventory [15, 16,
18], Hamilton Depression Scale [15, 16], and Montgomery–
Asberg Depression Rating Scale [17]. These studies
compared antidepressants with placebo and reported no
statistically signiﬁcant differences in depression [15–18].
Due to lack of data in three studies, only Dickens [17]
reported data on depression, a meta-analysis could not be
performed. Overall, these results suggest that there is very
low quality evidence (inconsistent, imprecise, and reporting
Table 2 Summary of effect estimates for pharmacological interventions
Outcome title No. of studies No. of
participants
Statistical method Effect size
NSAID’s
Comparison 01. NSAIDs versus placebo for chronic non-speciﬁc LBP, follow up B12 weeks
Change in Pain Intensity from baseline
on 100 mm VAS
4 1,020 Weighted mean difference
(ﬁxed) 95% CI
-12.40 [-15.53, -9.26]
Total adverse events 4 1,034 Relative risk (ﬁxed) 95% CI 1.24 [1.07, 1.43]
Antidepressants
Comparison 02. Antidepressants versus placebo for chronic non-speciﬁc LBP
Pain 4 292 Standardised mean difference
(random) 95% CI
-0.02 [-0.26, 0.22]
Adverse events 2 157 Relative risk (ﬁxed) 95% CI 0.93 [0.84, 1.04]
Comparison 03. SSRIs versus placebo
Pain 3 199 Standardised mean difference
(random) 95% CI
0.11 [-0.17, 0.39]
Comparison 04. TCAs versus placebo
Pain 2 104 Standardised mean difference
(random) 95% CI
-0.11 [-0.72, 0.51]
Opioids
Comparison 05. Opioids (all types) compared with placebo for chronic low back pain
Pain 7 2,350 Standardised mean difference
(ﬁxed) 95% CI
0.54 [-0.72, -0.36]
Disability 4 1,258 Standardised mean difference
(ﬁxed) 95% CI
-0.19 [-0.31, -0.08]
Adverse events 4 1,176 Relative risk (random) 95% CI 1.28 [1.14, 1.44]
46 Eur Spine J (2011) 20:40–50
123bias) that antidepressants do not seem to reduce depression
in patients with chronic LBP.
Antidepressants versus placebo: functional status One
study with a low RoB included functional status as an
outcome measure [17]. There is low-quality evidence (one
RCT; n = 92; inconsistency; imprecision) that there is no
difference in functional status with the use of antidepres-
sants compared to placebo in patients with LBP.
Antidepressant type versus placebo: pain intensity Two
pooled analyses were performed to evaluate the effect of
two types of antidepressants on pain intensity (Appendix 3,
graphs 03.01; 04.01 in Electronic Supplementary Mate-
rial). Two trials with a low RoB [16, 19] were pooled
comparing TCAs with placebo, including one trial with two
intervention arms [19]. Three trials with a low RoB [16, 17,
19] were pooled to compare SSRIs with placebo. There is
moderate evidence that SSRIs (three RCTs; n = 199;
limitations in design; SMD 0.11; 95% CI -0.17 to 0.39)
and TCAs (two RCTs; n = 104; limitations in design;
SMD -0.11; 95% CI -0.72 to 0.51) are not more effective
than placebo in reducing pain.
Adverse events Only two studies [15, 16] reported data
about any adverse event during the study. The pooled
results of these studies show that there is moderate evi-
dence (two RCTs; n = 157; limitations in design) that
there is no statistically signiﬁcant difference between
antidepressants and placebo in the occurrence of any
adverse event during the study (RR 0.93; 95% CI
0.84–1.04) (Appendix 3, graph 02.02 in Electronic Sup-
plementary Material). Adverse events that were frequently
reported in both groups were dry mouth, insomnia, seda-
tion, orthostatic symptoms and constipation.
In the study of Atkinson [19], adverse effects were
reported that interfered at least ‘mildly’ with everyday
function. Statistically signiﬁcantly (P\0.001) more
adverse effects were reported in the experimental arms,
desipramine n = 19 (63.3%) and ﬂuoxetine n = 16
(51.6%), as compared to placebo n = 3 (13.6%).
Sensitivity analysis In the Cochrane review, the inﬂuence
on the results was examined of the inclusion of the ‘posi-
tive’ trial by Atkinson [15], which did not report follow-up
means and SDs, by calculating the follow-up means for
pain intensity and depression from the baseline and change
scores with different methods. The inclusion of Atkinson
[15] n the meta-analyses for both pain and depression did
not change the conclusions, that there is no difference in
effect between antidepressants and placebo, and demon-
strates the robustness of the ﬁndings.
Similarly, the addition of three intervention arms from
the study by Atkinson [19] was examined in the meta-
analyses. This study did not report statistically signiﬁcant
results for the intention-to-treat analysis, only for the
‘complete cases analysis’. The Cochrane meta-analyses
showed that the inclusion of Atkinson [19] did not change
the conclusions for pain and antidepressant type.
Opioids
Opioids versus placebo: pain intensity A meta-analysis
was performed to combine the results of seven trials
[22–28]. Webster [27] and Vorsanger [28] included more
than one intervention arm. There is low quality evidence
(seven RCTs; n = 2,350; limitations in design; indirect-
ness) that those who received opioids reported greater pain
relief than those who received placebo (SMD -0.54; 95%
CI -0.72 to -0.36) (Appendix 3, graph 05.01 in Electronic
Supplementary Material).
Opioids versus placebo: functional status There is low
evidence (four RCTs; n = 1,258; limitations in design;
indirectness) that opioids (tramadol) are more efﬁcacious
than placebo for improving function as measured by the
Roland Disability Questionnaire (RDQ, score 0–24,
0 = no disability) (SMD -0.19 (95% CI -0.31 to 0.08)
(Appendix 3, graph 05.02 in Electronic Supplementary
Material).
Adverse events Four studies reported totals about adverse
events. There is low evidence (four RCTs; n = 1,176;
limitations in design; indirectness) that there are statisti-
cally signiﬁcantly more adverse events in patients using
opioids compared to placebo (RR 1.28; 95% CI 1.14–1.44)
(Appendix 3, graph 05.03 in Electronic Supplementary
Material). Adverse events most frequently reported were
headache and nausea.
In a sensitivity analysis the inﬂuence of the inclusion in
the analysis of patients with prior surgery was studied. We
compared studies which included patients with prior
surgery B1 year before entering the study or studies which
reported no information [23, 25–27] with studies which
included patients with prior surgery[1 year before inclu-
sion or studies which excluded patients with prior surgery
[22, 24, 28]. We found no differences in effect estimates
compared with our main analysis (data available on
request).
In another sensitivity analysis we studied the inﬂuence
of leaving studies out studies not studying tramadol as the
active agent. We found no differences in effect estimates
compared with our main analysis (data also available on
request).
Opioids versus other drugs Only one study [29] (high
RoB) compared opioids to another analgesic, i.e. naproxen.
There is very low quality evidence (one RCT; n = 23; limi-
tations in design; inconsistency; indirectness; imprecision)
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123that there is no difference in pain intensity (SMD -0.58;
95%CI-1.42to0.26)andfunction(SMD-0.06;95%CI-
0.88 to 0.76) between opioids compared to other drugs. This
was likely due to the small sample size. Jamison 1998 found
no improvement in function for opioids compared with
naproxen.
Discussion
In this review, 17 RCTs were included that evaluated the
effectiveness of pharmacological interventions for non-
speciﬁc chronic low back pain.
The effectiveness of the different pharmacological
interventions
No studies were found for muscle relaxants. In this review
we found low quality evidence for effects on pain intensity
for NSAIDs and opioids, and a small effect on function for
opioids compared to placebo on the short term
(\3 months) for patients with chronic low back pain. No
effects were found for the use of antidepressants compared
to placebo on any of the primary outcomes. NSAIDS and
opioids seem to be associated with more adverse effects
compared with placebo.
Methodological considerations
Despite the fact that the RoB of the studies was generally
low, many studies showed ﬂaws regarding concealment of
treatment allocation, compliance, and drop-out rates. We
feel the quality of future RCTs in the ﬁeld of low back pain
regarding these issues could be improved to reduce bias in
future systematic reviews and overviews.
In three of the four studies assessing NSAIDs for chronic
LBP and ﬁve of the eight studies on opioids, a so called
‘‘ﬂare design’’ was used, in which patients who were
already responding well to NSAIDs or opioids were only
included when they showed a large worsening in LBP
complaints during a wash-out period. This may have caused
favourable results of the investigated NSAIDs and opioids,
expressed in an overestimation of the effects and an
underestimation of the adverse effects due to the selection
of the study population, and certainly decreases the external
validity for daily practice. It is uncertain if the results also
apply to other patients with low back pain (who have not yet
received NSAIDs or opioids for their LBP episode).
Adverse effects
In the studies presented in this review adverse effects were
reported, although we would like to emphasize the need for
a complete and better report of adverse effects in clinical
trials. Clearly, smaller randomised trials are unlikely to
detect rare adverse events. Better reporting of adverse
events in larger trials or prospective cohort sties is required.
According to the authors of the studies on NSAIDs,
most adverse effects, including abdominal pain, diarrhea,
edema, dry mouth, rash, dizziness, headache, and tiredness,
were considered to be mild to moderately severe. However,
the sample sizes of most of the studies were relatively
small, and therefore no clear conclusion can be drawn from
these studies regarding the risks of gastrointestinal and
other adverse effects of NSAIDs. The statistical pooling of
all adverse effects of NSAIDs compared to placebo for
acute LBP indeed showed an increased RR, indicating the
additional risk of using NSAIDs.
For antidepressants adverse effects, such as dry mouth,
constipation, tachycardia, sedation, orthostatic hypoten-
sion, and tremor, were commonly reported, but no serious
adverse effects were documented. However, the trials were
also very small and not designed to evaluate adverse
effects.
For opioids adverse effects were reported extensively
and seemed to occur more in the opioid group compared to
placebo, although here as well the numbers are small.
Overall it is difﬁcult to draw ﬁrm conclusions regarding
the risks for adverse effects of NSAIDs, antidepressants
and opioids. Prospective studies with larger sample sizes
are necessary to evaluate the incidence of both minor and
major adverse effects.
Strengths and limitations
Several biases can be introduced in systematic reviews by
literature search and selection procedure. We might have
missed relevant unpublished trials, which are more likely to
be small studies without positive results, leading to publi-
cation bias. Screening references of identiﬁed trials and
systematic reviews may result in an over representation of
positive studies in the review, because trials with a positive
result are more likely to be referred to in other publications,
leasing to reference bias. Studies not published in English,
Dutch or German were not included in this review. It is not
clear whether a language restriction is associated with bias
[30].
Another important limitation was the poor reporting
of co-interventions, especially in the studies regarding
NSAIDs and antidepressants, which hampered the study of
the potential bias caused by this issue.
Implications for research
To conclude, we identiﬁed 17 RCTs that evaluated phar-
macological treatment effects for patients with chronic
48 Eur Spine J (2011) 20:40–50
123non-speciﬁc LBP. Most of the studies included in this
review had a low RoB, although there were methodological
weaknesses, especially regarding concealment of alloca-
tion, compliance, and drop-out rates. There is a need for
future high-quality RCTs with special emphasis on these
subjects.
Implications for practice
NSAIDs and opioids might be useful for short-term pain
relief in patients with chronic LBP, who responded with an
exacerbation of their symptoms after stopping their medi-
cation. However, possible adverse effects should be
weighed in deciding which medication to prescribe.
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